Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Carlton G Glenn who wrote (4688)	10/28/1997 1:26:00 PM
From: C Wright	Read Replies (3) \| Respond to of 9262

"Blue" on my screens ... nice to see all those "red" numbers start to disappear ... Is this just a tease? Hmmmmm. Nonetheless, still feels good. Carl, thanks for the link re gold... I'm researching this avenue. However, FWIW, a friend in investment banking has issued a word of caution to me on the gold issue...so I'm thinking twice and doing extra DD)... Good luck with whatever you decide. Hope your screens are all "blue." Carol

To: Carlton G Glenn who wrote (4688)	10/28/1997 2:37:00 PM
From: John Metcalf	Read Replies (1) \| Respond to of 9262

(CHAT) Thanks for the gold link, Carl. Of course there are market forces working here -:) Since you asked where I am looking for gains -- in biotechnology. DEPO, in particular, since it is 2 months from FDA resolution on its 1st product, and has shown up on the STO. In general, some contraction for the multi-national big pharmas that provide much of the cash for biotechs, will make the biotech barrel a little smaller, and the fish correspondingly larger. I am focusing on biotechs with adequate capital, unique development platforms, late stage products, and low cash burn. Premier among these is ArQule (ARQL). Some others worth consideration in this sale include BCHE, GLIA, and SEPR.